Cyclic Arg-Gly-Asp peptide-labeled liposomes for targeting drug therapy of hepatic fibrosis in rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 322, Issue 2, 2007, Pages 560-568

  Du, Shi Lin ^a   Pan, Hong ^a   Lu, Wei Yue ^a   Wang, Jian ^a   Wu, Jian ^b,c   Wang, Ji Yao ^a  

^a FUDAN UNIVERSITY   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 B INTERFERON; ALPHA INTERFERON DERIVATIVE; COLLAGEN TYPE 6; CYCLIC ARGINYLGLYCYLASPARTIC ACID; DRUG CARRIER; LIPOSOME; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT LIGATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG LABELING; DRUG RECEPTOR BINDING; DRUG STABILITY; DRUG TARGETING; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; LIVER CELL CULTURE; LIVER FIBROSIS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; STELLATE CELL; THERAPY EFFECT; TREATMENT RESPONSE;

ALANINE TRANSAMINASE; ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; CHOLESTASIS, EXTRAHEPATIC; COLLAGEN TYPE I; COLLAGEN TYPE III; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; GENE EXPRESSION; HEPATOCYTES; HYDROXYPROLINE; INTERFERON-ALPHA; LIVER; LIVER CIRRHOSIS; MALE; MALEIMIDES; OLIGOPEPTIDES; PEPTIDES, CYCLIC; PERICYTES; PHOSPHATIDYLETHANOLAMINES; POLYETHYLENE GLYCOLS; RATS; RATS, WISTAR; UNILAMELLAR LIPOSOMES;

EID: 34547137386     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.122481     Document Type: Article

References (34)

1. Adrian JE, Poelstra K, Scherphof GL, Meijer DK, van Loenen-Weemaes AM, Reker-Smit C, Morselt H, Zwiers P, and Kamps JA (2007) Effects of a new bioactive lipid-based drug carrier on cultured hepatic stellate cells and liver fibrosis in bile duct ligated rats. J Pharmacol Exp Ther 321:536-543.
2. Ahkong QF and Tilcock C (1992) Attachment of 99mTc to lipid vesicles containing the lipophilic chelate dipalmitoylphosphatidylethanolamine-DTTA. Int J Rad Appl Instrum B 19:831-840.
3. Aina OH, Marik J, Liu R, Lau DH, and Lam KS (2005) Identification of novel targeting peptides for human ovarian cancer cells using "one-bead one-compound" combinatorial libraries. Mol Cancer Ther 4:806-813.
4. Allen TM, Brandeis E, Hansen CB, Kao GY, and Zalipsky S (1995) A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim Biophys Acta 1237:99-108.
5. Beljaars L, Meijer DK, and Poelstra K (2002) Targeting hepatic stellate cells for cell-specific treatment of liver fibrosis. Front Biosci 7:e214-e222.
6. Beljaars L, Molema G, Schuppan D, Geerts A, De Bleser PJ, Weert B, Meijer DK, and Poelstra K (2000) Successful targeting to rat hepatic stellate cells using albumin modified with cyclic peptides that recognize the collagen type VI receptor. J Biol Chem 275:12743-12751.
7. Beljaars L, Molema G, Weert B, Bonnema H, Olinga P, Groothuis GM, Meijer DK, and Poelstra K (1999) Albumin modified with mannose 6-phosphate: a potential carrier for selective delivery of antifibrotic drugs to rat and human hepatic stellate cells. Hepatology 29:1486-1493.
8. Blume G, Cevc G, Crommelin MD, Bakker-Woudenberg IA, Kluft C, and Storm G (1993) Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times. Biochim Biophys Acta 1149:180-184.
9. Borkham-Kamphorst E, Herrmann J, Stoll D, Treptau J, Gressner AM, and Weiskirchen R (2004) Dominant-negative soluble PDGF-beta receptor inhibits hepatic stellate cell activation and attenuates liver fibrosis. Lab Invest 84:766-777.
10. Canbay A, Friedman S, and Gores GJ (2004) Apoptosis: the nexus of liver injury and fibrosis. Hepatology 39:273-278.
11. Dubey PK, Mishra V, Jain S, Mahor S, and Vyas SP (2004) Liposomes modified with cyclic RGD peptide for tumor targeting. J Drug Target 12:257-264.
12. Friedman SL (1999) Cytokines and fibrogenesis. Semin Liver Dis 19:129-140.
13. Inagaki Y, Nemoto T, Kushida M, Sheng Y, Higashi K, Ikeda K, Kawada N, Shirasaki F, Takehara K, Sugiyama K, et al. (2003) Interferon alfa down-regulates collagen gene transcription and suppresses experimental hepatic fibrosis in mice. Hepatology 38:890-899.
14. Jiang W, Yang CQ, Liu WB, Wang YQ, He BM, and Wang JY (2004) Blockage of transforming growth factor beta receptors prevents progression of pig serum-induced rat liver fibrosis. World J Gastroenterol 10:1634-1638.
15. Lee RJ and Low PS (1994) Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J Biol Chem 269:3198-3204.
16. Li D and Friedman SL (1999) Liver fibrogenesis and the role of hepatic stellate cells: new insights and prospects for therapy. J Gastroenterol Hepatol 14:618-633.
17. Liu L, Zern MA, Lizarzaburu ME, Nantz MH, and Wu J (2003) Poly(cationic lipid)-mediated in vivo gene delivery to mouse liver. Gene Ther 10:180-187.
18. Lu G, Shimizu I, Cui X, Itonaga M, Tamaki K, Fukuno H, Inoue H, Honda H, and Ito S (2002) Interferon-alpha enhances biological defense activities against oxidative stress in cultured rat hepatocytes and hepatic stellate cells. J Med Invest 49:172-181.
19. Marcelino J and McDevitt CA (1995) Attachment of articular cartilage chondrocytes to the tissue form of type VI collagen. Biochim Biophys Acta 1249:180-188.
20. Pan H, Niu GQ, Pan J, and Lu WY (2006) Preparation and in vitro targeting of sterically stabilized liposomes modified with chimeric TNT-3 monoclonal antibody. Yao Xue Xue Bao 41:506-512.
21. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, Ling MH, and Albrecht J (2002) Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122:1303-1313.
22. Reeves HL and Friedman SL (2002) Activation of hepatic stellate cells-a key issue in liver fibrosis. Front Biosci 7:d808-d826.
23. Saile B, Eisenbach C, El-Armouche H, Neubauer K, and Ramadori G (2003) Antiapoptotic effect of interferon-alpha on hepatic stellate cells (HSC): a novel pathway of IFN-alpha signal transduction via Janus kinase 2 (JAK2) and caspase-8. Eur J Cell Biol 82:31-41.
24. Strader DB, Wright T, Thomas DL, and Seeff LB (2004) Diagnosis, management, and treatment of hepatitis C. Hepatology 39:1147-1171.
25. Wu J, Liu L, Yen RD, Catana A, Nantz MH, and Zern MA (2004) Liposome-mediated extracellular superoxide dismutase gene delivery protects against acute liver injury in mice. Hepatology 40:195-204.
26. Wu J, Liu P, Zhu JL, Maddukuri S, and Zern MA (1998a) Increased liver uptake of liposomes and improved targeting efficacy by labeling with asialofetuin in rodents. Hepatology 27:772-778.
27. Wu J, Nantz MH, and Zern MA (2002) Targeting hepatocytes for drug and gene delivery: emerging novel approaches and applications. Front Biosci 7:d717-d725.
28. Wu J, Soderbergh H, Karlsson K, and Danielsson A (1996) Protective effect of S-adenosyl-L-methionine on bromobenzene- and D-galactosamine-induced toxicity to isolated rat hepatocytes. Hepatology 23:359-365.
29. Wu J, Wu GY, and Zern MA (1998b) The prospects of hepatic drug delivery and gene therapy. Expert Opin Investig Drugs 7:1795-1817.
30. Wu J and Zern MA (2000) Hepatic stellate cells: a target for the treatment of liver fibrosis. J Gastroenterol 35:665-672.
31. Yen YD, Zern MA, and Wu J (2006) Molecular therapy for hepatic fibrosis, in Trends in Chemotherapy Research (Weber MD ed) pp 1-123, Nova Science Publishers, Inc., Hauppauge, NY.
32. Zhan SS, Jiang JX, Wu J, Halsted C, Friedman SL, Zern MA, and Torok NJ (2006) Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo. Hepatology 43:435-443.
33. Zhang QS, Wang JY, and Hu MY (1999) Effects of interferon-α on the mRNA expression of procollagen type I and III of hepatic stellate cells and on the deposition of collagen type I and III in fibrotic liver of rats. Zhonghua Yi Xue Za Zhi 79:695-698.
34. Zhu J, Wu J, Frizell E, Liu SL, Bashey R, Rubin R, Norton P, and Zern MA (1999) Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis. Gastroenterology 117:1198-1204.